Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery

Juliet N Barker, MBBS, (Hons), FRACP, Doris M Ponce, MD, Parastoo B Dahi, MD, Sean Devlin, PhD, Katherine L Evans, BA, Marissa N Lubin, BA, Richard Meagher, PhD, Lilian Reich, MD, Hugo Castro-Malaspina, MD, Jenna D Goldberg, MD, Ann A. Jakubowski, MD, PhD, Guenther Koehne, MD, PhD, Esperanza B Papadopoulos, M.D., Miguel-Angel Perales, MD, Craig S. Sauter, MD, Andromachi Scaradavou, MD, Nancy A. Kernan, MD, Sergio A Giralt, MD, Richard J. O'Reilly, MD

Blood (2013) 122 (21): 298.

https://doi.org/10.1182/blood.V122.21.298.298

Published: 2013

Journal Articles

Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC),

Nelly G. Adel, PharmD, BCOP, BCPS, Elaine Duck, RN, MA, MS, Karen Collum, RN, MSN, OCN, Emily Mccullagh, NP_C, Lilian Reich, MD, Heather Landau, MD, Sergio Giralt, MD, Hani Hassoun, MD

Blood (2011) 118 (21): 4059.

https://doi.org/10.1182/blood.V118.21.4059.4059

Published: 2011

Journal Articles

Effect of Novel Agents on Stem Cell (SC) Mobilization and Engraftment In Patients with Multiple Myeloma (MM) at Memorial Sloan-Kettering Cancer Center

Melissa Pozotrigo, PharmD, Nelly G. Adel, PharmD, Vincent LaRussa, PhD, Xiaoshe Chen, PhD, Elyn Riedel, PhD, Lilian Reich, MD, Heather Landau, MD, Sergio Giralt, MD, Hani Hassoun, MD

Blood (2010) 116 (21): 2262.

https://doi.org/10.1182/blood.V116.21.2262.2262

Published: 2010

Journal Articles

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Hani Hassoun, MD, Brian T. Rafferty, MS, Carlos Flombaum, MD, Vivette D. D’Agati, MD, Virginia M. Klimek, MD, Adam Cohen, MD, Adam Boruchov, MD, Tarun Kewalramani, MD, Lilian Reich, MD, Heather Landau, MD, Stephen D. Nimer, MD, Raymond Comenzo, MD

Blood (2007) 110 (11): 5113.

https://doi.org/10.1182/blood.V110.11.5113.5113

Published: 2007

Journal Articles

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

Raymond Comenzo, MD, Hani Hassoun, MD, Lilian Reich, MD, Nancy Collins, PhD, Andre Nuta, Xiaoshe Chen, PhD, Ping Zhou, MD. PhD, Bradly Clark, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, David Wuest, MD, Stephen D. Nimer, MD

Blood (2006) 108 (11): 3087.

https://doi.org/10.1182/blood.V108.11.3087.3087

Published: 2006

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Tarun Kewalramani, MD, Madhav Dhodapkar, MD, Lisa Drake, Rachel Zimman, Cyrus V. Hedvat, MD, Teruya-Feldstein Julie, MD, Fleisher Martin, phD, Daniel A. Filippa, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2004) 104 (11): 2409.

https://doi.org/10.1182/blood.V104.11.2409.2409

Published: 2004

NARROW

Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery

Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC),

Effect of Novel Agents on Stem Cell (SC) Mobilization and Engraftment In Patients with Multiple Myeloma (MM) at Memorial Sloan-Kettering Cancer Center

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery

Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC),

Effect of Novel Agents on Stem Cell (SC) Mobilization and Engraftment In Patients with Multiple Myeloma (MM) at Memorial Sloan-Kettering Cancer Center

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only